William W. Ericson - 02 Jun 2021 Form 4 Insider Report for Adamas Pharmaceuticals Inc

Role: Director, 10%+ Owner
Signature: /s/ Christopher B. Prentiss, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 02 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 04 Jun 2021, 16:14:14 UTC
Previous filing: 26 May 2021
Next filing: 21 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMS	Common Stock	Award	$0	+5,000	+100%	$0.000000	10,000	02 Jun 2021	Direct	F1
holding	ADMS	Common Stock						4,031,804	02 Jun 2021	MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP	F2
holding	ADMS	Common Stock						287,992	02 Jun 2021	MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.	F3
holding	ADMS	Common Stock						265,150	02 Jun 2021	MDV VII, L.P.	F2
holding	ADMS	Common Stock						6,043	02 Jun 2021	MDV ENF VII (A), L.P.	F2
holding	ADMS	Common Stock						3,146	02 Jun 2021	MDV ENF VII (B), L.P.	F2
holding	ADMS	Common Stock						25,661	02 Jun 2021	MDV VII Leaders' Fund, L.P.	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMS	Stock Option (Right to Buy)	Award	$0	+10,000		$0.000000	10,000	02 Jun 2021	Common Stock	10,000	$5.21	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
F2	Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
F3	Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
F4	The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.